Page 10 | Certara

Announcement

Certara Releases Environmental, Social and Governance Report

The report highlights a commitment to sustainability and corporate responsibilities. RADNOR, Pa. – August 26,…

CertaraAugust 26, 2025

Blog

Top 5 Recommendations for Successful Interactive Value Messaging

August 22, 2025 Over the past two decades in health economics and market access, I’ve…

CertaraAugust 22, 2025

On-Demand Webinar

Blueprint for Biotech Success: De-risking Early Development to Secure Long-Term Value

Discover strategies to cut risk, speed timelines, and boost investor confidence in early biotech development.

CertaraAugust 21, 2025

On-Demand Webinar

ToxStudio®: In silico tools to accelerate toxicology assessments

Watch to explore ToxStudio—in silico toxicology platform designed to address key preclinical safety challenges.

CertaraAugust 19, 2025

On-Demand Webinar

Certara IQ™: The Scalable AI-Powered QSP Software

Discover how Certara's AI-powered QSP modeling software, Certara IQ is overcoming challenges in drug development…

CertaraAugust 19, 2025

On-Demand Webinar

The Many Challenges of Patient Narrative Writing | RAPS Sponsored Webinar

Watch Certara’s RAPS-sponsored on-demand webinar to learn how automation and expert strategies simplify patient narrative…

CertaraAugust 18, 2025

Case Study

Small Biotech Clinical Trial Application (CTA) & Investigational New Drug (IND) Submission Success with Integrated Project Management

Find out how Certara helped a small biotech achieve on-time IND and CTA submissions with…

CertaraAugust 18, 2025

Conference

BioTechX US 2025

– – Booth

Simona ColucciAugust 15, 2025

Blog

Accelerate your SDTM Mapping with Pinnacle 21 Enterprise Plus

Streamline your SDTM mapping with Pinnacle 21 Enterprise. Discover how innovation and efficiency enhance data…

CertaraAugust 13, 2025

Publication

Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma

Explore comprehensive population pharmacokinetic analyses of belantamab mafodotin, evaluating both monotherapy and combination regimens in…

CertaraAugust 13, 2025

Certara Releases Environmental, Social and Governance Report

Top 5 Recommendations for Successful Interactive Value Messaging

Blueprint for Biotech Success: De-risking Early Development to Secure Long-Term Value

ToxStudio®: In silico tools to accelerate toxicology assessments

Certara IQ™: The Scalable AI-Powered QSP Software

The Many Challenges of Patient Narrative Writing | RAPS Sponsored Webinar

Small Biotech Clinical Trial Application (CTA) & Investigational New Drug (IND) Submission Success with Integrated Project Management

BioTechX US 2025

Accelerate your SDTM Mapping with Pinnacle 21 Enterprise Plus

Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma

Newsletter sign up

Quick links

Solutions

Contact